Skip to Content

Join the 'Carbidopa / Levodopa' group to help and get support from people like you.

Carbidopa / Levodopa Blog

Exercise Benefits People With Parkinson's Disease: Study

Posted 6 days ago by Drugs.com

WEDNESDAY, June 24, 2015 – Parkinson's disease patients who begin regular exercise earlier have a much slower decline in quality of life than those who start exercising later, a new study finds. National Parkinson Foundation (NPF) researchers looked at information from nearly 3,000 patients. More than 1,300 reported doing little regular exercise before taking part in the study. Over two years, 500 of the inactive patients began to exercise more than 2.5 hours a week. The researchers compared patients who exercised regularly for the entire two years to people who were inactive at the start of the study, but then began a regular exercise routine. The study didn't note the type of workouts, just the total amount of exercise. After two years, scores on a questionnaire that measured the impact of Parkinson's on daily life in a number of areas – including mood, movement and social ... Read more

Related support groups: Benadryl, Parkinson's Disease, Diphenhydramine, Mirapex, Requip, Sinemet, Ropinirole, Pramipexole, Cogentin, Emsam, Benztropine, Levodopa, Bromocriptine, Azilect, Cabergoline, Carbidopa, Selegiline, Amantadine, Benadryl Allergy, Neupro

Ex-Baseball Star Kirk Gibson Has Parkinson's Disease

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Kirk Gibson, who played 17 seasons of Major League Baseball and is perhaps best known for a dramatic pinch-hit, ninth inning home run to win a World Series game in 1988, said Tuesday he has Parkinson's disease. Gibson, 57, a Michigan native who played 12 seasons with the Detroit Tigers, said in a statement that "I have faced many different obstacles in my life, and have always maintained a strong belief that no matter the circumstances, I could overcome those obstacles. "While this diagnosis poses a new kind of challenge for me, I intend to stay true to my beliefs," he added. "With the support of my family and friends, I will meet this challenge with the same determination and unwavering intensity that I have displayed in all of my endeavors in life. I look forward to being back at the ballpark as soon as possible." According to the U.S. National Institutes of ... Read more

Related support groups: Benadryl, Parkinson's Disease, Diphenhydramine, Mirapex, Requip, Sinemet, Ropinirole, Pramipexole, Cogentin, Emsam, Benztropine, Levodopa, Bromocriptine, Azilect, Cabergoline, Carbidopa, Selegiline, Amantadine, Benadryl Allergy, Neupro

FDA Approves Duopa (carbidopa and levodopa) Enteral Suspension for Parkinson's Disease

Posted 12 Jan 2015 by Drugs.com

NORTH CHICAGO, Ill., Jan. 12, 2015 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. Duopa was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the U.S. "There is unmet need for treatment options for patients with advanced Parkinson's disease. As the disease advances, it can be difficult to control motor features," said C. Warren Olanow, M.D., Professor, Department of Neurology and Department of ... Read more

Related support groups: Parkinson's Disease, Carbidopa/Levodopa

Impax Pharmaceuticals Announce FDA Approval of Rytary (carbidopa and levodopa) for Parkinson's Disease

Posted 12 Jan 2015 by Drugs.com

HAYWARD, Calif., Jan. 8, 2015 /PRNewswire/ – Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that the U.S. Food and Drug Administration (FDA) approved Rytary, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. Rytary is not for use in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors. "The FDA approval of Rytary (pronounced rye-TAR-ee) is an important new development for the treatment of Parkinson's disease and provides an extended-release carbidopa-levodopa product that treats Parkinson's disease," said Fred Wilkinson, president and CEO, Impax Laboratories. "Rytary is designed to address one of the most significant unmet needs for ... Read more

Related support groups: Parkinson's Disease, Carbidopa/Levodopa

Levodopa May Beat Newer Meds for Long-Term Parkinson's Care: Study

Posted 11 Jun 2014 by Drugs.com

WEDNESDAY, June 11, 2014 – When it comes to which drug works best for patients with newly diagnosed Parkinson's disease, older may still be better, a new study finds. Research published June 10 in The Lancet finds that the dopamine drug levodopa still outperforms newer medications for the long-term care of people newly diagnosed with Parkinson's. "This study lays to rest lingering questions among both people with Parkinson's disease and their doctors about which drug is most beneficial when first beginning treatment for the disease," said James Beck, vice president of scientific affairs at the Parkinson's Disease Foundation (PDF). In the largest-ever trial of Parkinson's disease treatment, levodopa offered patients better mobility and a higher quality of life than the two main alternatives – drugs called dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors. The study ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Stalevo, Carbidopa/Levodopa, Sinemet CR, Stalevo 100, Parcopa, Stalevo 150, Stalevo 200, Dopar, Stalevo 50, Carbidopa/Entacapone/Levodopa, Atamet, Larodopa

Experimental Gel May Help Those With Advanced Parkinson's

Posted 18 Apr 2012 by Drugs.com

WEDNESDAY, April 18 – A gel form of two common Parkinson's drugs delivered via a feeding tube-like device may help people with advanced disease reduce medication side effects and possibly avoid brain surgery. That's the report from researchers who found the experimental levodopa-carbidopa intestinal gel works better than a standard pill regimen in reducing "off" time in people with advanced Parkinson's disease. About 1 million people in the United States are living with Parkinson's disease, a progressive movement disorder marked by tremor, slowness and/or rigidity. The disease slowly destroys the nerve cells in the brain that produce the chemical dopamine, which controls muscle movement. Treatment with oral levodopa-carbidopa – brand names include Sinemet, Sinemet CR and Parcopa – helps replace dopamine levels, but higher doses and long-term use of the oral drugs can cause ... Read more

Related support groups: Parkinson's Disease, Sinemet, Carbidopa/Levodopa, Sinemet CR, Parcopa, Atamet

Parkinson's Drugs Linked to Behavior Problems in Study

Posted 30 Mar 2011 by Drugs.com

TUESDAY, March 29 – Parkinson's disease drugs called dopamine agonists appear to cause impulse control problems in almost one-quarter of patients, says a new study. Previous research has linked dopamine agonists, which include Mirapex (pramipexole) and Requip (ropinirole), to impulse control disorders, such as gambling addiction and hypersexuality, and to compulsive behaviors, such as binge eating, overspending and excessive computer use. In this study, Mayo Clinic researchers analyzed Parkinson's disease patient records over two years. "What we found was that as many as 22 percent of patients during that two-year period had a new-onset impulse control disorder," lead investigator and neurology fellow Dr. Anhar Hassan said in a Mayo Clinic news release. The higher the dose of dopamine agonist, the more likely a patient was to develop an impulse control disorder, the researchers found. ... Read more

Related support groups: Parkinson's Disease, Mirapex, Requip, Sinemet, Ropinirole, Pramipexole, Emsam, Levodopa, Bromocriptine, Azilect, Cabergoline, Carbidopa, Selegiline, Amantadine, Neupro, Parlodel, Dostinex, Stalevo, Carbidopa/Levodopa, Sinemet CR

Parkinson's Drugs Tied to Compulsive Behaviors

Posted 10 May 2010 by Drugs.com

MONDAY, May 10 – Medicines used to treat Parkinson's disease may increase the risk of impulse control disorders, such as problem gambling, compulsive shopping and binge eating, researchers warn. In a new study that included 3,090 patients being treated for Parkinson's at 46 movement disorder centers in the United States and Canada, the researchers found that 13.6 percent of the patients had impulse control disorders. These impulse disorders included gambling (5 percent), compulsive sexual behavior (3.5 percent), compulsive shopping (5.7 percent) and binge eating (4.3 percent), and nearly 4 percent of the patients had two or more of these disorders. Impulse control disorders were more common among patients taking dopamine agonist medications (17.1 percent) than in those not taking the drugs (6.9 percent), the study authors found. Other factors associated with impulse control disorders ... Read more

Related support groups: Parkinson's Disease, Mirapex, Requip, Sinemet, Ropinirole, Pramipexole, Emsam, Levodopa, Bromocriptine, Azilect, Cabergoline, Carbidopa, Selegiline, Amantadine, Neupro, Parlodel, Dostinex, Stalevo, Carbidopa/Levodopa, Sinemet CR

Cutting Parkinson's Drug Dose Linked to Withdrawal Effects

Posted 14 Jan 2010 by Drugs.com

WEDNESDAY, Jan. 13 – Reduced dosages of dopamine agonists, drugs routinely used to treat Parkinson's disease, can cause symptoms similar to those experienced by addicts in withdrawal, such as anxiety, panic attacks, pain, dizziness and drug cravings, researchers say. The symptoms of what the researchers have dubbed "dopamine agonist withdrawal syndrome" have been linked to a disruption in levels of dopamine in the brain, according to the study published in the Jan. 12 issue of the Archives of Neurology. "Like cocaine and methamphetamines, dopamine agonists work by stimulating the reward pathways in the brain," senior study author Dr. Melissa J. Nirenberg, said in a news release from Weill Cornell Medical Center. "For this reason, it makes sense that they would engender similar withdrawal symptoms, particularly in those with high cumulative drug exposure," explained Nirenberg, associate ... Read more

Related support groups: Parkinson's Disease, Mirapex, Requip, Sinemet, Ropinirole, Pramipexole, Emsam, Levodopa, Bromocriptine, Azilect, Carbidopa, Selegiline, Amantadine, Neupro, Parlodel, Stalevo, Carbidopa/Levodopa, Requip XL, Comtan, Sinemet CR

Ask a Question

Further Information

Related Condition Support Groups

Parkinson's Disease, Restless Legs Syndrome, Neuroleptic Malignant Syndrome, GTP-CH Deficiency

Related Drug Support Groups

Sinemet, Sinemet CR, Parcopa, Rytary, Atamet, Duopa

Carbidopa / Levodopa Patient Information at Drugs.com